New drug aims to soften skin and protect lungs in rare disease

NCT ID NCT07047690

Recruiting now Disease control Sponsor: Galderma R&D Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a drug called nemolizumab in 162 adults with systemic sclerosis, a disease that causes skin thickening and can harm internal organs. Participants receive either nemolizumab or a placebo as a shot under the skin for 52 weeks. The main goal is to see if the drug reduces skin hardness and to find the best dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Nemolizumab (a drug given as a shot under the skin)
What this could lead to: If it works, this could point toward a new treatment to control skin hardening and possibly slow lung damage in systemic sclerosis.
What could go wrong: This is an early Phase 2 trial with only 162 people, so results may not apply to everyone. The drug may not work better than placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse scleroderma interstitial lung disease limited cutaneous systemic sclerosis systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SYSTEMIC SCLEROSIS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Galderma Investigational Site # 6213
RECRUITING

Sankt Gallen, 9007, Switzerland
Galderma Investigational Site # 8743
RECRUITING

Ann Arbor, Michigan, 48109-5000, United States
Galderma Investigational Site#7096
RECRUITING

Arlington, Texas, 76012, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.